SEC Form 4 · accession 0001127602-16-046331
PDS Biotechnology Corp · PDSB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James J Loughlin
Director
Period of report
Mar 11, 2016
Accepted (ET)
Mar 15, 2016 · 4:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001472091
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 11, 2016 | P | 100 | $7.575 | A | 100 | I | Family Trust |
| Common StockF1 | Mar 11, 2016 | P | 13 | $7.627 | A | 113 | I | Family Trust |
| Common StockF1 | Mar 11, 2016 | P | 500 | $7.639 | A | 613 | I | Family Trust |
| Common StockF1 | Mar 11, 2016 | P | 1,107 | $7.6385 | A | 1,720 | I | Family Trust |
| Common StockF1 | Mar 11, 2016 | P | 600 | $7.6385 | A | 2,320 | I | Family Trust |
| Common StockF1 | Mar 11, 2016 | P | 500 | $7.627 | A | 2,820 | I | Family Trust |
| Common StockF1 | Mar 11, 2016 | P | 180 | $7.627 | A | 3,000 | I | Family Trust |
| Common Stock | holding | — | — | — | 19,625 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.